AU2001274459C1 - Pharmaceutical compositions comprising cannabidiol derivatives - Google Patents
Pharmaceutical compositions comprising cannabidiol derivatives Download PDFInfo
- Publication number
- AU2001274459C1 AU2001274459C1 AU2001274459A AU2001274459A AU2001274459C1 AU 2001274459 C1 AU2001274459 C1 AU 2001274459C1 AU 2001274459 A AU2001274459 A AU 2001274459A AU 2001274459 A AU2001274459 A AU 2001274459A AU 2001274459 C1 AU2001274459 C1 AU 2001274459C1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- general formula
- conditions
- straight
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical class OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 35
- 230000008569 process Effects 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 7
- 241000282414 Homo sapiens Species 0.000 claims abstract description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 72
- 150000001875 compounds Chemical class 0.000 claims description 61
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000004432 carbon atom Chemical group C* 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 230000036407 pain Effects 0.000 claims description 8
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- -1 dimethoxy compound Chemical class 0.000 claims description 6
- 150000002118 epoxides Chemical class 0.000 claims description 6
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 4
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- QLOKJRIVRGCVIM-UHFFFAOYSA-N 1-[(4-methylsulfanylphenyl)methyl]piperazine Chemical compound C1=CC(SC)=CC=C1CN1CCNCC1 QLOKJRIVRGCVIM-UHFFFAOYSA-N 0.000 claims description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 2
- DYDCAPNFPHATGL-UHFFFAOYSA-N [Mg+]C.CC(C)[N-]C1CCCCC1 Chemical compound [Mg+]C.CC(C)[N-]C1CCCCC1 DYDCAPNFPHATGL-UHFFFAOYSA-N 0.000 claims description 2
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- 238000007075 allylic rearrangement reaction Methods 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 238000006735 epoxidation reaction Methods 0.000 claims description 2
- 125000003700 epoxy group Chemical group 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- HVAMZGADVCBITI-UHFFFAOYSA-M pent-4-enoate Chemical compound [O-]C(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-M 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 claims description 2
- 229960002218 sodium chlorite Drugs 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 208000028017 Psychotic disease Diseases 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 230000002920 convulsive effect Effects 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 230000000926 neurological effect Effects 0.000 claims 3
- 239000006184 cosolvent Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 239000002563 ionic surfactant Substances 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract description 7
- 230000000049 anti-anxiety effect Effects 0.000 abstract description 7
- 230000002082 anti-convulsion Effects 0.000 abstract description 7
- 239000002249 anxiolytic agent Substances 0.000 abstract description 7
- 230000001093 anti-cancer Effects 0.000 abstract description 5
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 4
- 230000000561 anti-psychotic effect Effects 0.000 abstract description 4
- 230000000324 neuroprotective effect Effects 0.000 abstract description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 3
- 150000001336 alkenes Chemical class 0.000 description 76
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 76
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 35
- 229950011318 cannabidiol Drugs 0.000 description 30
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 29
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 29
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 27
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 15
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 239000000284 extract Substances 0.000 description 11
- ZELUXPWDPVXUEI-ZWKOTPCHSA-N 7-hydroxycannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(CO)=C1 ZELUXPWDPVXUEI-ZWKOTPCHSA-N 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229960000905 indomethacin Drugs 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 108700012920 TNF Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 229940114079 arachidonic acid Drugs 0.000 description 7
- 235000021342 arachidonic acid Nutrition 0.000 description 7
- 229930003827 cannabinoid Natural products 0.000 description 7
- 239000003557 cannabinoid Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 229920000392 Zymosan Polymers 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940089151 indomethacin 20 mg Drugs 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VQPVHIFSDPRZAC-ZBUVYOTDSA-N (2r,3r)-2-(2,6-dimethoxy-4-pentylphenyl)-6-methylidene-3-prop-1-en-2-ylcyclohexan-1-ol Chemical compound COC1=CC(CCCCC)=CC(OC)=C1[C@H]1[C@H](C(C)=C)CCC(=C)C1O VQPVHIFSDPRZAC-ZBUVYOTDSA-N 0.000 description 2
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 2
- KZHNYLAFFGASBN-UHFFFAOYSA-N 1-methylidene-2-prop-1-en-2-ylcyclohexane Chemical compound CC(=C)C1CCCCC1=C KZHNYLAFFGASBN-UHFFFAOYSA-N 0.000 description 2
- YVEPGCZIBQXPJW-FZWXSHBKSA-N 2-[(1r,6r)-2-hydroxy-3-methylidene-6-prop-1-en-2-ylcyclohexyl]-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(=C)C1O YVEPGCZIBQXPJW-FZWXSHBKSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- 0 C*c1c(C2C=C(C*)CCC2C(C)=C)c(OC)cc(*)c1 Chemical compound C*c1c(C2C=C(C*)CCC2C(C)=C)c(OC)cc(*)c1 0.000 description 2
- 101100219382 Caenorhabditis elegans cah-2 gene Proteins 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 241000452413 Sabra Species 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 229940065144 cannabinoids Drugs 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000506 psychotropic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinyl group Chemical group C1(O)=CC(O)=CC=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- KEEKMOIRJUWKNK-CABZTGNLSA-N (2S)-2-[[2-[(4R)-4-(difluoromethyl)-2-oxo-1,3-thiazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide Chemical compound FC([C@H]1N(C(SC1)=O)C=1N=C2N(CCOC3=C2C=CC(=C3)N[C@H](C(=O)N)C)C=1)F KEEKMOIRJUWKNK-CABZTGNLSA-N 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- MPJURNPNPDQYSY-UHFFFAOYSA-N 5-(2-methyloctan-2-yl)-2-(3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl)benzene-1,3-diol Chemical compound OC1=CC(C(C)(C)CCCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 MPJURNPNPDQYSY-UHFFFAOYSA-N 0.000 description 1
- ZELUXPWDPVXUEI-UHFFFAOYSA-N 7-Hydroxy-cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(CO)=C1 ZELUXPWDPVXUEI-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- FDBIADVBUPNGJZ-UHFFFAOYSA-N C(C)C(CCCCCC)C=1C=C(C=C(O)C1)O.CC(C(CC(CC)C)C)C=1C=C(C=C(O)C1)O.CC(CCCCCCC)C=1C=C(C=C(O)C1)O.CC(CCCCCCCC)C=1C=C(C=C(O)C1)O Chemical compound C(C)C(CCCCCC)C=1C=C(C=C(O)C1)O.CC(C(CC(CC)C)C)C=1C=C(C=C(O)C1)O.CC(CCCCCCC)C=1C=C(C=C(O)C1)O.CC(CCCCCCCC)C=1C=C(C=C(O)C1)O FDBIADVBUPNGJZ-UHFFFAOYSA-N 0.000 description 1
- UHGAVYSRMOPUJU-UHFFFAOYSA-N C1(O)=CC(O)=CC=C1.C(C)C(C(C)C)C=1C=C(C=C(O)C1)O.CC(CCCCCC)(C)C=1C=C(C=C(O)C1)O.CC(C(CCCC)C)C=1C=C(C=C(O)C1)O.CC(C(CCCCCC)C)C=1C=C(C=C(O)C1)O.CC(C(CCCCC)C)C=1C=C(C=C(O)C1)O Chemical compound C1(O)=CC(O)=CC=C1.C(C)C(C(C)C)C=1C=C(C=C(O)C1)O.CC(CCCCCC)(C)C=1C=C(C=C(O)C1)O.CC(C(CCCC)C)C=1C=C(C=C(O)C1)O.CC(C(CCCCCC)C)C=1C=C(C=C(O)C1)O.CC(C(CCCCC)C)C=1C=C(C=C(O)C1)O UHGAVYSRMOPUJU-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000012466 analgesic assay Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 244000261228 chanvre indien Species 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- UYYCVBASZNFFRX-UHFFFAOYSA-N n-propan-2-ylcyclohexanamine Chemical compound CC(C)NC1CCCCC1 UYYCVBASZNFFRX-UHFFFAOYSA-N 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- MCZDHTKJGDCTAE-UHFFFAOYSA-M tetrabutylazanium;acetate Chemical compound CC([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC MCZDHTKJGDCTAE-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/065—Diphenyl-substituted acyclic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL136839 | 2000-06-16 | ||
IL136839A IL136839A (en) | 2000-06-16 | 2000-06-16 | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
PCT/IL2001/000537 WO2001095899A2 (fr) | 2000-06-16 | 2001-06-12 | Compositions pharmaceutiques renfermant des derives de cannabidiol |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2001274459A1 AU2001274459A1 (en) | 2002-03-14 |
AU2001274459B2 AU2001274459B2 (en) | 2005-07-07 |
AU2001274459C1 true AU2001274459C1 (en) | 2006-02-02 |
Family
ID=11074281
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001274459A Ceased AU2001274459C1 (en) | 2000-06-16 | 2001-06-12 | Pharmaceutical compositions comprising cannabidiol derivatives |
AU7445901A Pending AU7445901A (en) | 2000-06-16 | 2001-06-12 | Pharmaceutical compositions comprising cannabidiol derivatives |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU7445901A Pending AU7445901A (en) | 2000-06-16 | 2001-06-12 | Pharmaceutical compositions comprising cannabidiol derivatives |
Country Status (11)
Country | Link |
---|---|
US (1) | US7759526B2 (fr) |
EP (1) | EP1289517B1 (fr) |
JP (1) | JP2004503498A (fr) |
AT (1) | ATE309798T1 (fr) |
AU (2) | AU2001274459C1 (fr) |
CA (1) | CA2411831C (fr) |
DE (1) | DE60115029T2 (fr) |
DK (1) | DK1289517T3 (fr) |
ES (1) | ES2254432T3 (fr) |
IL (1) | IL136839A (fr) |
WO (1) | WO2001095899A2 (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6995187B1 (en) * | 1999-10-18 | 2006-02-07 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
IL136839A (en) | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
US8449908B2 (en) * | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
WO2003063847A1 (fr) * | 2002-02-01 | 2003-08-07 | Gw Pharma Limited | Compositions comprenant du cannabinoides destinees au traitement de nausees, de vomissements, de mal des transports ou d'etats pathologiques similaires |
GB0202385D0 (en) * | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
IL148244A0 (en) | 2002-02-19 | 2002-09-12 | Yissum Res Dev Co | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
US7285687B2 (en) | 2002-04-25 | 2007-10-23 | Virginia Commonwealth University | Cannabinoids |
IL157849A0 (en) * | 2003-09-10 | 2004-03-28 | Yissum Res Dev Co | Pharmaceutical compositions containing (+) cannabidiol and derivatives thereof and some such novel derivatives |
IL159892A0 (en) * | 2004-01-15 | 2004-06-20 | Yissum Res Dev Co | Use of quinonoid derivatives of cannabinoids in the treatment of malignancies |
EP1869063A2 (fr) * | 2005-03-29 | 2007-12-26 | Regents Of The University Of Minnesota | Procedes de production d'esters 3 bioactif d'aldehyde betulinique et d'acide betulinique |
KR20080063800A (ko) | 2005-09-29 | 2008-07-07 | 에이엠알 테크놀로지, 인크. | 델타-9-테트라히드로칸나비놀의 제조 방법 |
US20100158973A1 (en) | 2006-03-13 | 2010-06-24 | Hadasit Medical Research Services & Development Llimited | Therapeutic uses of cannabidiol compounds |
US9763894B2 (en) | 2006-12-05 | 2017-09-19 | Virginia Commonwealth University | Inflammation therapy |
WO2009018389A1 (fr) * | 2007-07-30 | 2009-02-05 | Alltranz Inc. | Promédicaments de cannabidiol, compositions comprenant les promédicaments de cannabidiol et leurs procédés d'utilisation |
GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
US20090247619A1 (en) * | 2008-03-06 | 2009-10-01 | University Of Kentucky | Cannabinoid-Containing Compositions and Methods for Their Use |
WO2014062965A1 (fr) | 2012-10-17 | 2014-04-24 | Northeastern University | Ligands cannabinergiques de 2-cycloalkyl résorcinol |
US9889100B2 (en) | 2013-05-02 | 2018-02-13 | Mor Research Applications Ltd. | Cannabidiol for treatment of severe and refractory graft-versus-host disease |
EP2991733B1 (fr) | 2013-05-02 | 2020-02-19 | Mor Research Applications Ltd. | Cannabidiol destiné à la prévention et au traitement de la maladie du greffon contre l'hôte |
GB2516814B (en) | 2013-06-19 | 2016-08-31 | Otsuka Pharma Co Ltd | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2527599A (en) * | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
EP3232808B1 (fr) | 2014-12-19 | 2020-04-01 | THC Pharm GmbH The Health Concept | Boisson contenant du cbd |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
MX2018000844A (es) | 2015-07-22 | 2018-07-06 | Phytopharma Int Ltd | Composiciones ingeribles por abejas, procedimientos para el uso de las mismas para producir miel y miel producida de esta manera. |
US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
WO2017160923A1 (fr) * | 2016-03-15 | 2017-09-21 | Royal Oil Colorado Llc | Formulations d'huile d'argan et de cannabidiol |
CA3077624A1 (fr) | 2016-10-01 | 2018-04-05 | James Smeeding | Compositions pharmaceutiques comprenant une statine et un cannabinoide et leurs utilisations |
AU2018287018B2 (en) | 2017-06-20 | 2022-04-28 | University Of Guelph | Cannabidiolic acid esters compositions and uses thereof |
IL272709B2 (en) | 2017-09-08 | 2024-09-01 | Scicann Therapeutics Inc | The compounds containing cannabinoid and spilantol |
GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
WO2019222459A1 (fr) * | 2018-05-18 | 2019-11-21 | Diverse Biotech, Inc. | Préparations de cannabinoïdes et utilisations thérapeutiques |
JP2021535201A (ja) * | 2018-08-20 | 2021-12-16 | ベッソール ファルマ、エルエルシー | カンナビノイドの作成のためのプロセス |
CN112062697B (zh) * | 2019-05-22 | 2023-09-01 | 上海特化医药科技有限公司 | 间苯多酚衍生物及其制备方法 |
GB201910389D0 (en) * | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
US20220401381A1 (en) | 2019-11-08 | 2022-12-22 | Vella Bioscience, Inc. | Peripherally acting cannabidiol (cbd)-containing compounds and uses thereof for enhancing female sexual function or treating female sexual disorders |
CN111848365A (zh) * | 2020-07-16 | 2020-10-30 | 云南自由贸易试验区睿之成医药科技有限公司 | 一种大麻二酚的合成方法 |
US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
JP2023553335A (ja) | 2020-11-24 | 2023-12-21 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | カンナビノイド誘導体、及び、炎症、疼痛又は肥満の治療におけるそれらの使用 |
WO2022133544A1 (fr) * | 2020-12-23 | 2022-06-30 | Botanix Pharmaceuticals Limited | Cannabinoïdes cbd et analogues de cannabinoïdes cbd |
CN112898190B (zh) * | 2021-02-07 | 2023-10-24 | 中国科学院长春应用化学研究所 | 一种大麻二酚衍生物及其制备方法 |
WO2022238700A1 (fr) | 2021-05-12 | 2022-11-17 | GW Research Limited | Dérivés de cannabidiol-c4 pour le traitement de l'épilepsie |
WO2024069589A1 (fr) * | 2022-09-29 | 2024-04-04 | Blackstone Therapeutics, Llc | Analogues de cannabinoïdes et procédés d'utilisation pour le traitement et la prévention du cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH472435A (de) | 1965-06-02 | 1969-05-15 | Bayer Ag | Verfahren zur Herstellung von Estern phosphorhaltiger Säuren |
US5538993A (en) * | 1991-09-12 | 1996-07-23 | Yissum Research Development Company | Certain tetrahydrocannabinol-7-oic acid derivatives |
US5434295A (en) * | 1994-02-07 | 1995-07-18 | Yissum Research Development Company | Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds |
US5891465A (en) | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
US6235741B1 (en) | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
BR0009200A (pt) | 1999-03-22 | 2001-12-26 | Immugen Pharmaceuticals Inc | Compostos e composições para o tratamento dedoenças associada com disfunção imune |
IL136839A (en) | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
-
2000
- 2000-06-16 IL IL136839A patent/IL136839A/en not_active IP Right Cessation
-
2001
- 2001-06-12 CA CA2411831A patent/CA2411831C/fr not_active Expired - Fee Related
- 2001-06-12 DK DK01940973T patent/DK1289517T3/da active
- 2001-06-12 US US10/311,554 patent/US7759526B2/en not_active Expired - Fee Related
- 2001-06-12 ES ES01940973T patent/ES2254432T3/es not_active Expired - Lifetime
- 2001-06-12 WO PCT/IL2001/000537 patent/WO2001095899A2/fr active IP Right Grant
- 2001-06-12 AT AT01940973T patent/ATE309798T1/de not_active IP Right Cessation
- 2001-06-12 JP JP2002510078A patent/JP2004503498A/ja not_active Withdrawn
- 2001-06-12 DE DE60115029T patent/DE60115029T2/de not_active Expired - Lifetime
- 2001-06-12 EP EP01940973A patent/EP1289517B1/fr not_active Expired - Lifetime
- 2001-06-12 AU AU2001274459A patent/AU2001274459C1/en not_active Ceased
- 2001-06-12 AU AU7445901A patent/AU7445901A/xx active Pending
Also Published As
Publication number | Publication date |
---|---|
US7759526B2 (en) | 2010-07-20 |
IL136839A (en) | 2006-12-10 |
DK1289517T3 (da) | 2006-04-03 |
ATE309798T1 (de) | 2005-12-15 |
US20030166727A1 (en) | 2003-09-04 |
IL136839A0 (en) | 2001-06-14 |
EP1289517B1 (fr) | 2005-11-16 |
JP2004503498A (ja) | 2004-02-05 |
AU2001274459B2 (en) | 2005-07-07 |
ES2254432T3 (es) | 2006-06-16 |
WO2001095899A8 (fr) | 2004-04-29 |
WO2001095899A2 (fr) | 2001-12-20 |
CA2411831C (fr) | 2010-07-20 |
WO2001095899A3 (fr) | 2002-08-08 |
DE60115029T2 (de) | 2006-08-03 |
CA2411831A1 (fr) | 2001-12-20 |
DE60115029D1 (de) | 2005-12-22 |
AU7445901A (en) | 2001-12-24 |
EP1289517A2 (fr) | 2003-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001274459C1 (en) | Pharmaceutical compositions comprising cannabidiol derivatives | |
AU2001274459A1 (en) | Pharmaceutical compositions comprising cannabidiol derivatives | |
USRE42700E1 (en) | Induction of apoptosis in cancer cells | |
JPH08510241A (ja) | レチノイド様活性を有するテトラヒドロナフチルおよびシクロプロピル置換1,3−ブタジエン | |
Marco-Contelles et al. | From seeds of Apium graveolens linn. To a cerebral ischemia medicine: the long journey of 3-n-Butylphthalide | |
JP4846581B2 (ja) | ベンゾトロポロン誘導体および炎症反応の緩和 | |
US4485116A (en) | Antiprotozoal compounds | |
Zeng et al. | Saponin from Periploca forrestii schltr mitigates oxazolone‐induced atopic dermatitis via modulating macrophage activation | |
US7884133B2 (en) | Pharmaceutical compositions containing (+) cannabidioil and derivatives thereof and some such novel derivatives | |
KR0173455B1 (ko) | 치환된 피롤화합물 | |
Gupta et al. | Recent advances in the chemistry and biology of bakuchiol and its derivatives: An updated review | |
US3626012A (en) | Naphthyl acetaldehydes and derivatives thereof | |
CZ318795A3 (en) | Application of natural products and corresponding synthetic compounds for treating cardiovascular diseases | |
JP6464180B2 (ja) | アセチルサリチル酸ダイマー、その合成、ならびに補体媒介性障害の予防および治療のためのその使用 | |
US4279922A (en) | Photosensitizing benzofuranacrylics | |
AU2004276040B2 (en) | Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics | |
AU2004282055B2 (en) | Novel phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient | |
JP4541879B2 (ja) | ケイ皮酸二量体、その製造方法及び退行性脳疾患治療のためのその用途 | |
US3803174A (en) | Substituted xanthone carboxylic acid compounds | |
Marion et al. | THE VINYL SIDE-CHAIN IN GELSEMINE1 | |
Maxwell | Syntheses of Seven-Membered Ring Compounds | |
Jin et al. | Protective Activity of Alpha‐Mangostin against UVB‐Induced Injury in HaCaT Cells by Modulating the Ceramide and MAPK and NF‐κB Signaling Pathways | |
JP2008509994A (ja) | 乾癬の治療のための組成物および方法 | |
CHAN | I: PREPARATION OF (-)-CIS-2, 4-DIMETHYLCYCLOHEXANONE FROM (POS. ROT.)-PULEGONE. II: THE FAVORSKII REARRANGEMENT OF PULEGONE DIBROMIDE. III: EXPERIMENTS DIRECTED TOWARD THE TOTAL SYNTHESIS OF LUPEOL. IV: THE CYCLIZATION OF 3-ISOPROPENYL-6-OXOHEPTANOIC ACID INTO 2, 4-DIHYDROXY-2, 4-DIMETHYLCYCLOHEXANE-1-ACETIC ACID-, GAMMA-LACTONES. V: THE REACTION OF ENAMINES WITH CARBON-TETRACHLORIDE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JUL 2005. |
|
FGA | Letters patent sealed or granted (standard patent) | ||
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JUL 2005 |
|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |